English

BioStock: FDA approves Alligator’s phase II trial

Report this content

Alligator BioScience continues to make headways with its lead cancer immunotherapy candidate mitazalimab. The company reported positive interim data from its phase II OPTIMIZE-1 trial in metastatic pancreatic cancer in January. Now Alligator has received FDA authorization to start a new phase II trial, OPTIMIZE-2, in urothelia carcinoma. BioStock reached out to Alligator’s CEO Søren Bregenholt for a comment.

Read the interview with Søren Bregenholt at biostock.se:

FDA approves Alligator’s phase II trial - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: FDA approves Alligator’s phase II trial - BioStock
Tweet this